In this review, we provide the state of the art about brain metastases (BMs) from gestational trophoblastic neoplasia (GTN), a rare condition. Data concerning the epidemiology, clinical presentation, innovations in therapeutic modalities, and outcomes of GTN BMs are comprehensively presented with particular attention to the role of radiotherapy, neurosurgery, and the most recent chemotherapy regimens. Good response rates have been achieved thanks to multi-agent chemotherapy, but brain involvement by GTNs entails significant risks for patients’ health since sudden and extensive intracranial hemorrhages are possible. Moreover, despite the evolution of treatment protocols, a small proportion of these patients ultimately develops a resistant disease. To tackle this unmet clinical need, immunotherapy has been recently proposed. The role of this novel option for this subset of patients as well as the achieved results so far are also discussed.

From Uterus to Brain: An Update on Epidemiology, Clinical Features, and Treatment of Brain Metastases From Gestational Trophoblastic Neoplasia

Borella F.
Co-first
;
Cosma S.
Co-first
;
Preti M.;Gallio N.;Valabrega G.;Scotto G.;Rolfo A.;Castellano I.;Cassoni P.;Bertero L.
Co-last
;
Benedetto C.
Co-last
2022

Abstract

In this review, we provide the state of the art about brain metastases (BMs) from gestational trophoblastic neoplasia (GTN), a rare condition. Data concerning the epidemiology, clinical presentation, innovations in therapeutic modalities, and outcomes of GTN BMs are comprehensively presented with particular attention to the role of radiotherapy, neurosurgery, and the most recent chemotherapy regimens. Good response rates have been achieved thanks to multi-agent chemotherapy, but brain involvement by GTNs entails significant risks for patients’ health since sudden and extensive intracranial hemorrhages are possible. Moreover, despite the evolution of treatment protocols, a small proportion of these patients ultimately develops a resistant disease. To tackle this unmet clinical need, immunotherapy has been recently proposed. The role of this novel option for this subset of patients as well as the achieved results so far are also discussed.
12
859071
859079
https://www.frontiersin.org/articles/10.3389/fonc.2022.859071/full
brain metastases (BMs); chemotherapy; choriocarcinoma; gestational trophoblastic neoplasia; immunotherapy; treatment outcomes
Borella F.; Cosma S.; Ferraioli D.; Preti M.; Gallio N.; Valabrega G.; Scotto G.; Rolfo A.; Castellano I.; Cassoni P.; Bertero L.; Benedetto C.
File in questo prodotto:
File Dimensione Formato  
2022 Benedetto-fonc-12-859071.pdf

Accesso aperto

Tipo di file: PDF EDITORIALE
Dimensione 332.84 kB
Formato Adobe PDF
332.84 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1858648
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 1
social impact